Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 999
Filtrer
1.
Pol Przegl Chir ; 96(3): 1-8, 2024 Jun 24.
Article de Anglais | MEDLINE | ID: mdl-38940246

RÉSUMÉ

<b>Introduction:</b> Hemorrhoidal disease is the most common disease treated in proctology ambulatories. Conservative treatment is the basic form of treatment for this disease. One of the elements of treatment may be preparations with myoand phlebotropic effects.<b>Aim:</b> To assess the effect of a multi-ingredient myophlebotropic dietary supplement used as an adjunct on the rate and effectiveness of symptom relief in patients with stage II and III hemorrhoidal disease.<b>Material and method:</b> Patients with stage II and III hemorrhoidal disease with clinical symptoms such as pain, burning, itching and bleeding were qualified for the study. The patients were divided into two groups. The control group (Group I) of 29 patients receiving standard local treatment plus placebo and the study group (Group II) of 32 patients receiving the same local treatment and a six-component myophlebotropic product. Symptoms were analyzed at the time of inclusion in the study (day 0), after 4 and 10 days of therapy. The severity of hemorrhoidal disease and the feeling of relief were assessed on the day of inclusion (W0) and after 30 days of therapy.<b>Results:</b> There were no statistical differences between the groups in terms of disease advancement, age, gender, and duration of symptoms. Compared to the moment of inclusion in the study (W0), after 4 days (W1), after 10 days (W2) of taking the multi- -component product, there was a statistically significant improvement in the VAS scale: spontaneous pain and pain during defecation. In the qualitative assessment (yes/no), there were statistically significantly fewer cases of burning in the anus and itching. The treatment did not affect the rate of spontaneous bleeding, which was low at the beginning of the study, but significantly reduced the rate of bleeding during defecation. After 30 days of observation, it was found that the improvement in the severity of hemorrhoidal disease symptoms was significantly higher in the group using the tested preparation. Relief after a month of the study (one-question method) was noted in the group of patients receiving the tested product.<b>Conclusions:</b> The tested six-component myophlebotropic product proved to be effective in reducing the severity of symptoms such as spontaneous pain, pain during defecation, burning/burning in the anus and bleeding during defecation. Statistical significance was demonstrated in the symptom's relief and reduction in the severity of hemorrhoidal disease.


Sujet(s)
Hémorroïdes , Humains , Hémorroïdes/thérapie , Femelle , Mâle , Adulte d'âge moyen , Adulte , Résultat thérapeutique , Compléments alimentaires , Sujet âgé
2.
World J Gastroenterol ; 30(17): 2332-2342, 2024 May 07.
Article de Anglais | MEDLINE | ID: mdl-38813050

RÉSUMÉ

BACKGROUND: Hemorrhoidal artery embolization (Emborrhoid) is a novel method for the treatment of severe hemorrhoidal bleeding. Despite having a technical success rate of 93%-100%, the clinical success ranges between 63% and 94%, with a rebleeding rate of 13.6%. AIM: To evaluate the effectiveness of this procedure in reducing hemorrhoidal flow and hemorrhoidal bleeding. METHODS: This prospective observational pilot study was conducted at Division of General Surgery 1 and Tertiary Referral Pelvic Floor Center, Treviso Regional Hospital, Italy. In a 2 months period (February-March 2022), consecutive patients with hemorrhoidal bleeding scores (HBSs) ≥ 4, Goligher scores of II or III, failure of non-operative management, and a candidate for Emborrhoid were included. Endoanal ultrasound with eco-Doppler was performed preoperatively and 1 month after the procedure. The primary endpoint was to quantify the changes in arterial hemorrhoidal flow after treatment. The secondary endpoint was to evaluate the correlation between the flow changes and the HBS. RESULTS: Eleven patients underwent Emborrhoid. The overall pretreatment mean systolic peak (MSP) was 14.66 cm/s. The highest MSP values were found in the anterior left lateral (17.82 cm/s at 1 o'clock and 15.88 cm/s at 3 o'clock) and in the posterior right lateral (14.62 cm/s at 7 o'clock and 16.71 cm/s at 9 o'clock) quadrants of the anal canal. After treatment, the overall MSP values were significantly reduced (P = 0.008) although the correlation between MSP and HBS changes was weak (P = 0.570). A statistical difference was found between distal embolization compared with proximal embolization (P = 0.047). However, the coil landing zone was not related to symptoms improvement (P = 1.000). A significant difference in MSP changes was also reported between patients with type 1 and type 2 superior rectal artery (SRA) anatomy (P = 0.040). No relationship between hemorrhoidal grades (P = 1.000), SRA anatomy (P = 1.000) and treatment outcomes was found. CONCLUSION: The preliminary findings of this pilot study confirm that Emborrhoid was effective in reducing the arterial hemorrhoidal flow in hemorrhoidal disease. However, the correlation between the post-operative MSP and HBS changes was weak. Hemorrhoidal grade, SRA anatomy and type of embolization were not related to treatment outcomes.


Sujet(s)
Canal anal , Embolisation thérapeutique , Hémorroïdes , Échographie-doppler , Humains , Embolisation thérapeutique/méthodes , Embolisation thérapeutique/effets indésirables , Hémorroïdes/thérapie , Hémorroïdes/imagerie diagnostique , Hémorroïdes/chirurgie , Projets pilotes , Femelle , Mâle , Études prospectives , Adulte d'âge moyen , Résultat thérapeutique , Adulte , Sujet âgé , Canal anal/vascularisation , Canal anal/imagerie diagnostique , Artères/imagerie diagnostique , Endosonographie/méthodes , Hémorragie gastro-intestinale/thérapie , Hémorragie gastro-intestinale/étiologie , Hémorragie gastro-intestinale/imagerie diagnostique , Récidive
3.
Surg Clin North Am ; 104(3): 473-490, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38677814

RÉSUMÉ

Hemorrhoids and anal fissures are two of the most common benign anorectal diseases. Despite their high prevalence, diagnostic accuracy of benign anorectal disease is suboptimal at 70% for surgeons, especially for hemorrhoidal diseases. Once the diagnosis is correctly made, numerous medical and surgical treatment options are available, each with different rates of success and complications. In this article, the authors review each step of patient management, with emphasis on evidence-based treatment options for hemorrhoids and anal fissures. The article discusses the pathophysiology, diagnosis, medical management, and procedures for hemorrhoids followed by a detailed overview on the management of anal fissures.


Sujet(s)
Fissure anale , Hémorroïdectomie , Hémorroïdes , Hémorroïdes/thérapie , Hémorroïdes/diagnostic , Hémorroïdes/étiologie , Humains , Fissure anale/thérapie , Fissure anale/diagnostic , Fissure anale/étiologie , Fissure anale/physiopathologie , Hémorroïdectomie/méthodes
4.
Pan Afr Med J ; 47: 66, 2024.
Article de Anglais | MEDLINE | ID: mdl-38681103

RÉSUMÉ

Bowel transit disturbances favored by pregnancy and injuries during childbirth would be triggering or aggravating factors for anal pathologies. The objective of this work was to study the epidemiology, diagnosis, and treatment of anal pathologies during pregnancy and 6 weeks after delivery. We carried out a prospective, multi-centric, and analytical study in 10 obstetric units in Bamako from June 1st, 2019, to May 31st, 2020. After informed consent, we enrolled all first-trimester pregnant women admitted to the hospitals and who were followed up through the postpartum. We conducted a rectal examination in each participant and an anoscope in those with an anal symptom. Hemorrhoidal diseases were diagnosed in the case of external hemorrhoids (thrombosis or prolapse) or internal hemorrhoids. During the study period, we followed up 1,422 pregnant women and we found 38.4% (546) with anal pathologies (hemorrhoidal diseases in 13% (192), anal fissure in 10.5% (150) and anal incontinence in 8.6% (123). Risk factors for the hemorrhoidal disease were age of patient ≥30 years old aRR=5.77, 95% CI 4.57-7.34; p=0.000; a existence of chronic constipation aRR=2.61, 95% CI 1.98-3.44; p=0.000; newborn weight >3500 g aRR= 1.61, 95% CI 1.25-2.07; p=0.000 and fetal expulsion time >20 minutes aRR= 6.04, 95% CI 5.07-7.27; p=0.000. The clinical signs observed were constipation, anal pain, bleeding, and pruritus. The treatment was based on counseling on hygiene and diet, the use of laxatives, local topicals, and analgesics along perineal rehabilitation. Anal pathologies were common during pregnancy and 6 weeks after delivery. Pregnant women must be screened systematically for such pathologies. Early diagnostic and appropriate treatment would reduce serious complications.


Sujet(s)
Maladies de l'anus , Hémorroïdes , Période du postpartum , Complications de la grossesse , Humains , Femelle , Grossesse , Mali/épidémiologie , Adulte , Études prospectives , Hémorroïdes/épidémiologie , Hémorroïdes/diagnostic , Hémorroïdes/thérapie , Complications de la grossesse/épidémiologie , Complications de la grossesse/diagnostic , Complications de la grossesse/thérapie , Jeune adulte , Facteurs de risque , Maladies de l'anus/épidémiologie , Maladies de l'anus/diagnostic , Maladies de l'anus/thérapie , Fissure anale/diagnostic , Fissure anale/thérapie , Fissure anale/épidémiologie , Incontinence anale/épidémiologie , Incontinence anale/étiologie , Incontinence anale/diagnostic , Constipation/épidémiologie , Constipation/diagnostic , Études de suivi , Adolescent
5.
BMC Gastroenterol ; 24(1): 103, 2024 Mar 13.
Article de Anglais | MEDLINE | ID: mdl-38481133

RÉSUMÉ

BACKGROUND: Doctors are at high risk of developing hemorrhoidal disease (HD), but it is unclear whether doctors are aware of this risk. The OASIS (dOctors AS patIentS) study was performed to examine the prevalence, awareness, diagnosis, and treatment of HD among doctors in big cities in China. METHODS: An online survey consisting of a structured questionnaire was carried out among doctors in grade-A tertiary hospitals in 29 provinces across China from August to October 2020. RESULTS: A total of 1227 questionnaire responses were collected. HD prevalence was 56.8%, with a significant difference between internists and surgeons (P = 0.01). 15.6% of doctors with HD didn't have serious concerns about the recurrence and severity of HD. 91.5% of doctors adopted general treatments, and 83.0% considered oral medications only when topical medications were ineffective. Among the oral medications, Micronized Purified Flavonoid Fraction (MPFF) was most effective based on the scores from three important parameters, but only 17% of doctors received MPFF. CONCLUSIONS: Doctors are at higher risk of developing HD with a high prevalence among Chinese doctors, but they are not fully aware or not concerned about HD. There is a deficiency in treatment recommendations and clinical management of HD even for doctors, including late initiation and inadequate oral drug therapy. Therefore, awareness and standardized treatment of HD should be improved among Chinese doctors, as well as in the general population.


Sujet(s)
Hémorroïdes , Humains , Hémorroïdes/thérapie , Hémorroïdes/traitement médicamenteux , Centres de soins tertiaires , Villes , Enquêtes et questionnaires , Internet , Chine/épidémiologie
6.
Arab J Gastroenterol ; 25(2): 165-169, 2024 May.
Article de Anglais | MEDLINE | ID: mdl-38403495

RÉSUMÉ

BACKGROUND AND STUDY AIMS: Endoscopic minimally invasive treatment of internal hemorrhoids may cause postoperative pain. The aim of the study is to investigate the analgesic effect of lidocaine plus lauromacrogol on postoperative pain caused by endoscopic rubber band ligation (ERBL) combined with injection sclerotherapy (IS) for internal hemorrhoids treatment. PATIENTS AND METHODS: Clinical data of grade Ⅲ internal hemorrhoids patients who underwent ERBL combined with IS in department of Digestive Medicine, Shenzhen Hospital of Southern Medical University, were retrospectively analyzed. According to difference in the composition of sclerosing solution, the patients were divided into control group (lauromacrogol group, 46 patients) and study group (lidocaine plus lauromacrogol group, 20 patients). Postoperative pain (quantized by Visual Analogue Scale, VAS), pain relief time and postoperative adverse reactions were compared. The therapeutic effect was followed up 1 month after operation. RESULTS: VAS of postoperative pain was 0.80 ± 0.42 points and pain relief time was 0.90 ± 0.56 days in the study group, while VAS of postoperative pain was 4.11 ± 1.37 points and pain relief time was 2.57 ± 0.83 days in the control group, there was statistical difference between them (P < 0.05). There was no significant difference in the incidence of postoperative adverse reactions and follow-up therapeutic effect between the control group and the study group. CONCLUSION: Lidocaine plus lauromacrogol is useful for pain alleviation on ERBL combined with IS for internal hemorrhoids treatment because of its convenient procedure, low adverse reaction incidence and good therapeutic effect, which is worthy of promotion.


Sujet(s)
Anesthésiques locaux , Hémorroïdes , Lidocaïne , Mesure de la douleur , Douleur postopératoire , Sclérothérapie , Humains , Hémorroïdes/thérapie , Hémorroïdes/chirurgie , Lidocaïne/administration et posologie , Lidocaïne/usage thérapeutique , Études rétrospectives , Sclérothérapie/méthodes , Sclérothérapie/effets indésirables , Douleur postopératoire/prévention et contrôle , Douleur postopératoire/étiologie , Mâle , Ligature/méthodes , Femelle , Adulte d'âge moyen , Anesthésiques locaux/administration et posologie , Adulte , Solutions sclérosantes/administration et posologie , Solutions sclérosantes/usage thérapeutique , Polidocanol/administration et posologie , Polidocanol/usage thérapeutique , Association thérapeutique , Sujet âgé
7.
Tech Coloproctol ; 28(1): 28, 2024 01 23.
Article de Anglais | MEDLINE | ID: mdl-38261136

RÉSUMÉ

BACKGROUND: This systematic review and meta-analysis aimed to evaluate the safety and efficacy of sclerotherapy methods for hemorrhoidal disease (HD) over the past 40 years. METHODS: The review followed the 2020 Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. A comprehensive literature search was conducted, including studies reporting the use of sclerotherapy in patients with HD. Study eligibility criteria were defined, and data were extracted independently by the authors. Random-effects meta-analyses were performed to assess outcomes of interest. RESULTS: Out of 1965 records identified, 44 studies met the inclusion criteria, involving 9729 patients. The majority of studies were conducted in Japan, followed by the UK, Italy, and Portugal. The median age of participants was 52 years, and the majority were male. The Goligher grade distribution indicated varying degrees of HD severity. Sclerotherapy was predominantly administered through anoscopy, with polidocanol being the most commonly used agent. The procedure was generally performed without pre-injection analgesia. The meta-analysis of 14 randomized controlled trials (RCTs) revealed that sclerotherapy was not inferior to control interventions in terms of success rate (risk ratio [RR] 1.00, 95% CI 0.71-1.41) and recurrence rate (RR 1.11, 95% CI 0.69-1.77), while resulting in fewer complications (RR 0.46, 95% CI 0.23-0.92). CONCLUSIONS: This systematic review highlights the safety and efficacy of sclerotherapy for HD, which yields similar success rates and fewer complications compared to other conservative or surgical approaches. Further research is warranted to optimize sclerotherapy techniques and evaluate long-term outcomes. REGISTRATION: PROSPERO 2023 CRD42023396910.


Sujet(s)
Hémorroïdes , Sclérothérapie , Mâle , Humains , Femelle , Adulte d'âge moyen , Sclérothérapie/effets indésirables , Hémorroïdes/thérapie , Italie , Odds ratio , Polidocanol
9.
Surg Clin North Am ; 103(6): 1153-1170, 2023 Dec.
Article de Anglais | MEDLINE | ID: mdl-37838461

RÉSUMÉ

Anorectal emergencies are rare presentations of common anorectal disorders, and surgeons are often called on to assist in their diagnosis and management. Although most patients presenting with anorectal emergencies can be managed nonoperatively or with a bedside procedure, surgeons must also be able to identify surgical anorectal emergencies, such as gangrenous rectal prolapse. This article provides a review of pertinent anatomy; examination techniques; and workup, diagnosis, and management of common anorectal emergencies including thrombosed hemorrhoids, incarcerated hemorrhoids, anal fissure, anorectal abscess, rectal prolapse, and pilonidal abscess and unique situations including rectal foreign body and anorectal sexually transmitted infections.


Sujet(s)
Maladies de l'anus , Fissure anale , Hémorroïdes , Maladies du rectum , Prolapsus rectal , Humains , Hémorroïdes/thérapie , Hémorroïdes/chirurgie , Prolapsus rectal/diagnostic , Prolapsus rectal/thérapie , Abcès/diagnostic , Abcès/thérapie , Urgences , Maladies du rectum/diagnostic , Maladies du rectum/thérapie , Maladies de l'anus/diagnostic , Maladies de l'anus/thérapie , Fissure anale/diagnostic , Fissure anale/thérapie
10.
J Womens Health (Larchmt) ; 32(12): 1394-1401, 2023 Dec.
Article de Anglais | MEDLINE | ID: mdl-37582215

RÉSUMÉ

Background: Hemorrhoids, a gastrointestinal tract disorder, are common during pregnancy. However, large-scale epidemiological studies on hemorrhoids during pregnancy are limited. Therefore, this study used analyzed data from a nationwide population-based database to investigate the prevalence, characteristics, and treatment of hemorrhoids in Taiwan. Materials and Methods: This retrospective population-based study used data from the National Health Insurance Research Database and Taiwan Birth Certificate Application to collect the medical records of women who were pregnant at any time during 2009-2018. Hemorrhoids was defined by International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) (455. X) and International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) (K64.X, O22.4X) with related treatment. Results: We enrolled 1,608,804 deliveries in 1,070,708 women. The proportion of hemorrhoids increased with age in both primipara and multipara women. Of the pregnant women, 31% received oral medication, and 93.2% used the topical ointment to treat their hemorrhoids. Few patients (1.8%) required procedure or surgery during pregnancy, and 41.4% of those patients underwent procedure or surgery in their first trimester. The cumulative incidence of hemorrhoids during pregnancy was significantly higher in women with a history of hemorrhoids and those with multifetal pregnancies. No significant difference in the incidence of hemorrhoids was observed between multiparous and primiparous women. Conclusion: Women with a history of hemorrhoids or those carrying multiple fetuses had an increased risk of hemorrhoids during pregnancy. The most commonly used treatment for hemorrhoids during pregnancy was topical ointments, with only a small proportion (1.8%) of patients requiring procedure or surgery.


Sujet(s)
Hémorroïdes , Grossesse , Humains , Femelle , Hémorroïdes/épidémiologie , Hémorroïdes/thérapie , Études rétrospectives , Études de cohortes , Taïwan/épidémiologie , Prévalence
11.
Colorectal Dis ; 25(9): 1832-1838, 2023 09.
Article de Anglais | MEDLINE | ID: mdl-37475163

RÉSUMÉ

AIM: In this study we aimed to assess the responsiveness of the symptom score of the recently developed Patient-Reported Outcome Measure-Haemorrhoidal Impact and Satisfaction Score (PROM-HISS). Furthermore, the minimally relevant difference (MRD) was determined. METHOD: The responsiveness of PROM-HISS was tested using a criterion-based (i.e. anchor) and construct-based (i.e. hypotheses testing) approach. Patients with haemorrhoidal disease (HD) completed the PROM-HISS before and 1 week after treatment in hospital. A global self-assessment of change question (SCQ) was administered 1-week after treatment and functioned as the criterion. The following analyses were performed: (1) correlation between the PROM-HISS symptom score and the criterion (SCQ) and (2) hypotheses testing. The MRD was determined as change in symptoms of the subgroup reporting 'somewhat fewer complaints' on the SCQ. RESULTS: Between February and August 2022, 94 patients with grade II-IV HD from three hospitals were included. The correlation between the SCQ and a change on the PROM-HISS symptom score was 0.595 indicating that an improvement on the SCQ corresponds to an improvement on the PROM-HISS symptom score. As hypothesized, the mean change in PROM-HISS scores was significantly different between subgroups of patients based on their SCQ responses. Patients reporting a small change in HD symptoms on the SCQ corresponded to a mean change of 0.3 on the PROM-HISS symptom score. CONCLUSION: The PROM-HISS symptom score is a responsive instrument as it identifies change in HD symptoms because of treatment. The estimated MRD of 0.3 can be used to inform clinical research and practice.


Sujet(s)
Hémorroïdes , Humains , Enquêtes et questionnaires , Hémorroïdes/diagnostic , Hémorroïdes/thérapie , Satisfaction des patients , Mesures des résultats rapportés par les patients , Satisfaction personnelle
12.
Eur Radiol ; 33(12): 8754-8763, 2023 Dec.
Article de Anglais | MEDLINE | ID: mdl-37458757

RÉSUMÉ

OBJECTIVES: To evaluate the safety and efficacy of catheter-directed hemorrhoidal embolization (CDHE) by microcoil embolization for rectal bleeding due to hemorrhoids classified as Goligher grade I-III. METHODS: Eighty patients (62.5% males) with a mean age of 48 ± 9 years were recruited prospectively. All patients had symptomatic bleeding hemorrhoids. All patients were classified according to Goligher classification: grade I (13.7%), grade II (71.1%), grade III (15%), and no grade IV were recruited in this study. In all cases, microcoils were used to embolize the superior rectal artery(SRA), and microspheres if recurrence of bleeding occurred. Follow-up evaluation (1, 3, 6, and 12 months) included clinical examination and anoscopy. A questionnaire was conducted to determine improvement regarding bleeding, quality of life before, and the degree of patient satisfaction of each participant. RESULTS: Technical success was achieved in 100% of the cases. Fifty-five (68.7%) participants had the absence of rectal bleeding after 12 months of embolization. VAS and QL improved 4 points and 1.5 respectively after embolization. A total of 25/80 (31.3%) had a recurrence in rectal bleeding. Seventeen (21.3%) patients underwent a second embolization, and four patients (5%) were treated with open hemorrhoidectomy. No major complications were observed. Sixteen participants had minor complications. Subjective post-treatment symptom and QL surveys showed significant differences from the baseline survey. Likewise, the degree of satisfaction in the telephone survey at 12 months revealed a high degree of patient satisfaction (8.3±1.1). CONCLUSIONS: The present study demonstrates that CDHE is a feasible, well-tolerated, ambulatory, anal sphincter-sparing procedure for the treatment of internal hemorrhoids. CLINICAL RELEVANCE STATEMENT: CDHE is a simple procedure, well tolerated and accepted by patients, that preserves the anal sphincter and presents few complications when metal devices or microspheres are used as embolic agents. KEY POINTS: • The technical success rate of CDHE, defined as the closure of all the SRA in their distal segment, was achieved 100% of all patients. However, a second embolization treatment was required since 21.25% of the patients experienced rectal bleeding. • Overall, CDHE's safety profile is acceptable. After the procedure and 1 year of follow-up, no significant complications were observed. • Encouraging clinical outcomes have demonstrated CDHE in individuals with hemorrhoids and mild prolapse Goligher grades I-III with persistent rectal bleeding.


Sujet(s)
Hémorroïdes , Mâle , Humains , Adulte , Adulte d'âge moyen , Femelle , Hémorroïdes/complications , Hémorroïdes/thérapie , Canal anal , Études prospectives , Qualité de vie , Résultat thérapeutique , Traitements préservant les organes , Hémorragie gastro-intestinale/étiologie , Hémorragie gastro-intestinale/thérapie , Cathéters
13.
Prim Care ; 50(3): 461-480, 2023 Sep.
Article de Anglais | MEDLINE | ID: mdl-37516514

RÉSUMÉ

Benign conditions of the colon and rectum are a heterogeneous group of conditions that range from inflammatory to infectious to pelvic floor health conditions that affect large segments of the US population. These conditions include diverticular disease, hemorrhoids, and anorectal lesions. The initial presentation of these very common conditions often occurs in the outpatient primary care setting, and most can be managed by the primary care clinician. This article will provide an overview on the prevalence, diagnosis, and management of some of the most common benign colorectal disorders; these are broadly divided into diverticular disease, hemorrhoids, and anorectal conditions.


Sujet(s)
Tumeurs colorectales , Maladies diverticulaires , Fissure anale , Hémorroïdes , Humains , Hémorroïdes/diagnostic , Hémorroïdes/épidémiologie , Hémorroïdes/thérapie , Soins ambulatoires
14.
Trials ; 24(1): 374, 2023 Jun 03.
Article de Anglais | MEDLINE | ID: mdl-37270601

RÉSUMÉ

INTRODUCTION: Haemorrhoidal disease (HD) is a common condition with significant epidemiologic and economic implications. While it is possible to treat symptomatic grade 1-2 haemorrhoids with rubber band ligation (RBL) or sclerotherapy (SCL), the effectiveness of these treatments compatible with current standards has not yet been investigated with a randomised controlled trial. The hypothesis is that SCL is not inferior to RBL in terms of symptom reduction (patient-related outcome measures (PROMs)), patient experience, complications or recurrence rate. METHODS AND ANALYSIS: This protocol describes the methodology of a non-inferiority, multicentre, randomised controlled trial comparing rubber band ligation and sclerotherapy for symptomatic grade 1-2 haemorrhoids in adults (> 18 years). Patients are preferably randomised between the two treatment arms. However, patients with a strong preference for one of the treatments and refuse randomisation are eligible for the registration arm. Patients either receive 4 cc Aethoxysklerol 3% SCL or 3 × RBL. The primary outcome measures are symptom reduction by means of PROMs, recurrence and complication rates. Secondary outcome measures are patient experience, number of treatments and days of sick leave from work. Data are collected at 4 different time points. DISCUSSION: The THROS trial is the first large multicentre randomised trial to study the difference in effectivity between RBL and SCL for the treatment of grade 1-2 HD. It will provide information as to which treatment method (RBL or SCL) is the most effective, gives fewer complications and is experienced by the patient as the best option. ETHICS AND DISSEMINATION: The study protocol has been approved by the Medical Ethics Review Committee of the Amsterdam University Medical Centers, location AMC (nr. 2020_053). The gathered data and results will be submitted for publication in peer-reviewed journals and spread to coloproctological associations and guidelines. TRIAL REGISTRATION: Dutch Trial Register NL8377 . Registered on 12-02-2020.


Sujet(s)
Hémorroïdectomie , Hémorroïdes , Adulte , Humains , Hémorroïdes/diagnostic , Hémorroïdes/thérapie , Sclérothérapie/effets indésirables , Ligature/méthodes , Protocoles cliniques , Essais contrôlés randomisés comme sujet , Études multicentriques comme sujet
15.
Rev Prat ; 73(3): 270-273, 2023 Mar.
Article de Français | MEDLINE | ID: mdl-37289114

RÉSUMÉ

NEW PARADIGM FOR HAEMORRHOIDAL DISEASE TREATMENT. The modern surgical management of hemorrhoidal disease was born in 1937, without any great variation until the 90s. Later then, the quest for a surgery without pain or secondary complications has stimulated the appearance of new techniques, often dependent on sophisticated technologies, the most recent being still under evaluation. At the same time, conventional excision surgery has evolved to become less aggressive. Overall, the requirement for less morbidity has become a priority, exceeding that of the long-term efficacy, and the cost of those interventions based on sophisticated technologies has significantly increased.


CHANGEMENT DE PARADIGME DANS LA PRISE. EN CHARGE DE LA PATHOLOGIE HÉMORROÏDAIRELa prise en charge chirurgicale moderne de la maladie hémorroïdaire est née en 1937, sans grande variation jusque dans les années 1990. À partir de cette période, l'exigence d'une chirurgie moins douloureuse et sans séquelles a stimulé l'apparition de nouvelles techniques reposant le plus souvent sur des technologies sophistiquées, les plus récentes étant encore en cours d'évaluation. Parallèlement, la chirurgie d'exérèse classique a évolué pour devenir moins agressive. Au total, l'exigence de moindre morbidité est devenue prioritaire, l'efficacité à long terme secondaire, et l'arrivée des nouvelles technologies a augmenté le c oût direct de ces interventions.


Sujet(s)
Hémorroïdes , Humains , Sujet âgé de 80 ans ou plus , Hémorroïdes/thérapie , Douleur , Morbidité , Résultat thérapeutique
16.
Infect Disord Drug Targets ; 23(6): e270423216271, 2023.
Article de Anglais | MEDLINE | ID: mdl-37106517

RÉSUMÉ

BACKGROUND: Hemorrhoid disease (HD) is an anal-rectal ailment that is commonly painful or may be painless and causes rectal bleeding with or without prolapsing anal tissue. It is generally associated with bleeding, prolapse, pruritus, and discomfort, which results in a diminished quality of life and well-being. OBJECTIVE: To highlight the recent developments in terms of safety, clinical efficacy, and marketed formulation for the effective management of hemorrhoids. METHOD: Reported literature available on Scopus, PubMed, Science Direct, Clinicaltrails.gov, and from many reputed foundations has been studied to summarize the recent development and clinical studies for the management of hemorrhoids. RESULTS AND CONCLUSION: The high incidence of hemorrhoids obliges the development of new molecules; therefore, safe and efficient drugs to confer protection against hemorrhoids are urgently needed. This review article mainly focuses on the newer molecules to overcome hemorrhoids and also emphasizes various studies carried out in the past.


Sujet(s)
Hémorroïdes , Humains , Hémorroïdes/épidémiologie , Hémorroïdes/thérapie , Qualité de vie , Ligature/méthodes , Hémorragie gastro-intestinale , Résultat thérapeutique
17.
Dtsch Med Wochenschr ; 148(8): 483-496, 2023 04.
Article de Allemand | MEDLINE | ID: mdl-36990121

RÉSUMÉ

This article provides a practice-oriented overview of the most common proctological diseases: Anal eczema, hemorrhoidal disease, anal thrombosis, marisca, anal abscess and fistula, and anal fissure. Definitions and etiopathogenesis, clinic and diagnostics, and current therapy are presented.


Sujet(s)
Maladies de l'anus , Chirurgie colorectale , Fissure anale , Hémorroïdes , Humains , Maladies de l'anus/étiologie , Maladies de l'anus/thérapie , Fissure anale/diagnostic , Fissure anale/thérapie , Fissure anale/complications , Hémorroïdes/diagnostic , Hémorroïdes/thérapie , Hémorroïdes/complications , Rectum
18.
J Vasc Interv Radiol ; 34(5): 745-749, 2023 05.
Article de Anglais | MEDLINE | ID: mdl-36736822

RÉSUMÉ

PURPOSE: To evaluate the safety and efficacy of outpatient transarterial embolization for symptomatic refractory internal hemorrhoids. MATERIALS AND METHODS: Retrospective analysis of 134 patients who underwent hemorrhoidal artery embolization (HAE) for symptomatic internal hemorrhoids between August 2021 and June 2022 (76 men and 58 women) was performed. The mean age was 54.9 years, with a mean Goligher hemorrhoid grade (HG) of 2.1. Branches of the superior rectal artery (SRA) or middle rectal artery supplying the corpus cavernosum recti were embolized with both spherical particles and microcoils. Standard-of-care evaluations were performed at baseline and the 1 month follow-up, which included hemorrhoid-related pain (HRP) (0-10), hemorrhoid symptoms score (HSS) (5-20), quality of life (QoL) (0-4), French bleeding score (FBS) (0-9), and HG (0-4). Clinical success was defined as improvement of symptoms without additional treatment. RESULTS: Embolization of at least 1 hemorrhoidal artery was achieved in 133 (99%) of the 134 patients. The mean number of SRA branches embolized per patient was 2.9 ± 1.0. Clinical success was seen in 93% (124 of 134) of patients at the 1-month follow-up, with 10 patients requiring repeat embolization. There were significant improvements in all mean outcomes at 1 month: HSS (11-7.8; P < .01), HRP (4.1-1.3; P < .01), QoL (2.2-0.8; P < .01), FBS (4.4-2.2; P < .01), and HG (2.3-1.2; P < .05). There were no severe adverse events. CONCLUSIONS: HAE is a safe and effective outpatient treatment for refractory symptomatic internal hemorrhoids in the short term.


Sujet(s)
Hémorroïdes , Mâle , Humains , Femelle , Adulte d'âge moyen , Hémorroïdes/imagerie diagnostique , Hémorroïdes/thérapie , Qualité de vie , Patients en consultation externe , Études rétrospectives , Hémorragie/étiologie , Hémorragie/thérapie , Résultat thérapeutique , Artères/imagerie diagnostique , Ligature
19.
Arab J Gastroenterol ; 24(2): 85-90, 2023 May.
Article de Anglais | MEDLINE | ID: mdl-36379860

RÉSUMÉ

BACKGROUND AND STUDY AIMS: Outlet obstructive constipation (OOC) is a common type of chronic constipation that is usually caused by internal hemorrhoids (IH) and rectal mucosal prolapse (RMP). Cap-assisted endoscopic sclerotherapy (CAES) was demonstrated to be effective in the treatment of IH and RMP. This study explored the efficacy of CAES in treating OOC associated with IH and RMP. METHODS: Thirty-one patients (15 males and 16 females) were diagnosed with OOC after colonoscopy and anorectal manometry (AM). CAES was used to treat IH and RMP. The self-rating anxiety scale (SAS), self-rating depression scale (SDS), and Wexner constipation score (WCS) were used to assess patients at baseline and at the end of follow-up. AM tests were performed before and after CAES. RESULTS: The mean age of patients was 56.19 ± 7.969 years, and the follow-up time was 2.875 ± 3.703 months. After CAES treatment, subjective indices, including frequency of bowel movements (p < 0.05), defecation time (p < 0.05), SAS (p < 0.05), SDS (p < 0.05), and WCS (p < 0.05), were significantly improved. AM showed that the anal relaxation rate (p < 0.05), maximum squeeze pressure (p < 0.05), and rectal residual pressure (p < 0.05) were significantly improved. The ratio of Bristol stool form scale typeIII-Vincreased from 12.5 % to 56.25 % (p < 0.05). CONCLUSIONS: CAES is effective for treating OOC caused by IH and RMP. The relief of OOC symptoms could improve anxiety and depression symptoms associated with the disease.


Sujet(s)
Hémorroïdes , Prolapsus rectal , Mâle , Femelle , Humains , Adulte d'âge moyen , Sclérothérapie/effets indésirables , Prolapsus rectal/complications , Prolapsus rectal/thérapie , Prolapsus rectal/diagnostic , Constipation/étiologie , Constipation/thérapie , Constipation/diagnostic , Rectum , Hémorroïdes/complications , Hémorroïdes/thérapie , Canal anal , Manométrie/effets indésirables , Défécation
20.
Rev. esp. enferm. dig ; 115(3): 115-120, 2023. ilus, tab
Article de Anglais | IBECS | ID: ibc-217234

RÉSUMÉ

Purpose: Polidocanol foam sclerotherapy (SP) versus doppler-guided hemorrhoidal artery ligation with recto-anal repair (HAL-RAR) in the treatment of hemorrhoidal disease (HD) was analyzed. Methods: A prospective, randomized study including patients with HD grades II and III was performed. Participants were randomly assigned (1:1) into SP or HAL-RAR, during a recruitment period between September 2019 and February 2020. Therapeutic success (Sodergren’s and bleeding scores) was the primary outcome. Other outcomes evaluated included complications and implication in the professional life. Efficacy and safety outcomes were evaluated during the 8 weeks after surgery or the final SP session. Results: Forty-six patients were allocated either to SP (n=22) or HAL-RAR (n=24). Most patients achieved therapeutic success (SP 100% vs. HAL-RAR 90.9%, p=0.131). Complete success was higher in the SP group (91.7% vs. 68.2%, p=0.045) and SP patients had less complications (25% vs. 68.2%, p=0.003). HAL-RAR had a greater negative impact on work activity of the patient. Conclusion: SP was more effective and safer than HAL-RAR. SP patients had less impact on their work activity. Clinical trials identifier NCT04675177 (AU)


Sujet(s)
Humains , Mâle , Femelle , Adulte , Adulte d'âge moyen , Sujet âgé , Polidocanol/usage thérapeutique , Sclérothérapie/méthodes , Hémorroïdes/thérapie , Ligature , Indice de gravité de la maladie , Résultat thérapeutique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...